Expanding the armamentarium for the spondyloarthropathies

Arthritis Research and Therapy

Volumn 6, Issue SUPPL. 2, 2004, Pages

  Peloso, Paul M ^a   Braun, Jürgen ^b  

^a UNIVERSITY OF IOWA HEALTH CARE   (United States)

^b RHEUMAZENTRUM RUHRGEBIET   (Germany)

Author keywords

Efficacy; Etanercept; Infliximab; Spondyloarthropathies; Tumor necrosis factor

Indexed keywords

ADALIMUMAB; ETANERCEPT; HLA B27 ANTIGEN; INFLIXIMAB; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; ANTIRHEUMATIC AGENT;

ANKYLOSING SPONDYLITIS; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CROHN DISEASE; DISEASE PREDISPOSITION; EARLY DIAGNOSIS; ENTERITIS; HEREDITY; HUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PATHOGENESIS; PSORIATIC ARTHRITIS; RADIODIAGNOSIS; REVIEW; SACROILIAC JOINT; SPONDYLOARTHROPATHY; DIAGNOSTIC IMAGING; METHODOLOGY;

ANTIRHEUMATIC AGENTS; DIAGNOSTIC IMAGING; HUMANS; SPONDYLARTHROPATHIES;

EID: 28744447119     PISSN: 14786354     EISSN: None     Source Type: Journal    
DOI: 10.1186/ar1012     Document Type: Review

References (63)

1. Lawrence RC, Helmick CG, Arnett FC, Deyo RA, Felson DT, Giannini EH, Heyse SP, Hirsch R, Hochberg MC, Hunder GG, Liang MH, Pillemer SR, Steen VD, Wolfe F: Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. Arthritis Rheum 1998, 41:778-799.
2. Lau CS, Burgos-Vargas R, Louthrenoo W, Mok MY, Wordsworth P, Zeng QY: Features of spondyloarthritis around the world. Rheum Dis Clin North Am 1998, 24:753-770.
3. van der Linden S, Van Der Heijde D: Spondyloarthropathies. In Kelley's Textbook of Rheumatology. Edited by Ruddy S, Harris ED Jr, Sledge CB. Philadelphia: W.B. Saunders Company; 2001:1039-1053.
4. Francois RJ, Eulderink F, Bywaters EG: Commented glossary for rheumatic spinal diseases, based on pathology. Ann Rheum Dis 1995, 54:615-625.
5. Zink A, Braun J, Listing J, Wollenhaupt J, and the German Collaborative Arthritis Centers: Disability and handicap in rheumatoid arthritis and ankylosing spondylitis - results from the German rheumatological database. J Rheumatol 2000, 27:613-622.
6. Boonen A, Chorus A, Miedema H, Van Der Heijde D, van der Tempel H, van der Linden S: Employment, work disability, and work days lost in patients with ankylosing spondylitis: a cross sectional study of Dutch patients. Ann Rheum Dis 2001, 60: 353-358.
7. Boonen A, Severens JL: Ankylosing spondylitis: what is the cost to society, and can it be reduced? Best Pract Res Clin Rheumatol 2002, 16:691-705.
8. Lehtinen K: Mortality and causes of death in 398 patients admitted to hospital with ankylosing spondylitis. Ann Rheum Dis 1993, 52:174-176.
9. Radford EP, Doll R, Smith PG: Mortality among patients with ankylosing spondylitis not given X-ray therapy. N Engl J Med 1977, 297:572-576.
10. Myllykangas-Luosujärvi R, Aho K, Lehtinen K, Kautiainen H, Hakala M: Increased incidence of alcohol-related deaths from accidents and violence in subjects with ankylosing spondylitis. Br J Rheumatol 1998, 37:688-690.
11. Gonzalez-Roces S, Alvarez MV, Gonzalez S, Dieye A, Makni H, Woodfield DG, Housan L, Konenkov V, Abbadi MC, Grunnet N, Coto E, Lopez-Larrea C: HLA-B27 polymorphism and worldwide susceptibility to ankylosing spondylitis. Tissue Antigens 1997, 49:116-123.
12. Braun J, Bollow M, Remlinger G, Eggens U, Rudwaleit M, Distler A, Sieper J: Prevalence of Spondyloarthropathies in HLA-B27 positive and negative blood donors. Arthritis Rheum 1998, 41:58-67.
13. Rubin LA, Amos CI, Wade JA, Martin JR, Bale SJ, Little AH, Gladman DD, Bonney GE, Rubenstein JD, Siminovitch KA: Investigating the genetic basis for ankylosing spondylitis: linkage studies with the major histocompatibility complex region. Arthritis Rheum 1994, 37:1212-1220.
14. Laloux L, Voisin MC, Allain J, Martin N, Kerboull L, Chevalier X, Claudepierre P: Immunohistological study of entheses in Spondyloarthropathies: comparison in rheumatoid arthritis and osteoarthritis. Ann Rheum Dis 2001, 60:316-321.
15. Chang CP, Schumacher HR Jr: Light and electron microscopic observations on the synovitis of ankylosing spondylitis. Semin Arthritis Rheum 1992, 22:54-65.
16. Braun J, Bollow M, Neure L, Seipelt E, Seyrekbasan F, Herbst H, Eggens U, Distler A, Sieper J: Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis. Arthritis Rheum 1995, 38:499-505.
17. Matsuno H, Yudoh K, Katayama R, Nakazawa F, Uzuki M, Sawai T, Yonezawa T, Saeki Y, Panayi GS, Pitzalis C, Kimura T: The role of TNF-́ in the pathogenesis of inflammation and joint destruction in rheumatoid arthritis (RA): a study using a human RA/SCID mouse chimera. Rheumatology (Oxford) 2002, 41:329-337.
18. Cope AP, Aderka D, Doherty M, Engelmann H, Gibbons D, Jones AC, Brennan FM, Maini RN, Wallach D, Feldmann M: Increased levels of soluble tumor necrosis factor receptors in the sera and synovial fluid of patients with rheumatic diseases. Arthritis Rheum 1992, 35:1160-1169.
19. Plevy SE, Landers CJ, Prehn J, Carramanzana NM, Deem RL, Shealy D, Targan SR: A role for TNF-alpha and mucosal T helper-1 cytokines in the pathogenesis of Crohn's disease. J Immunol 1997, 159:6276-6282.
20. Braun J, Xiang J, Brandt J, Maetzel H, Haibel H, Wu P, Kohler S, Rudwaleit M, Siegert S, Radbruch A, Thiel A, Sieper J: Treatment of spondyloarthropathies with antibodies against tumour necrosis factor a: first clinical and laboratory experiences. Ann Rheum Dis 2000, 59(suppl 1):i85-i89.
21. Miller MH, Lee P, Smythe HA, Goldsmith CH: Measurements of spinal mobility in the sagittal plane: new skin contraction technique compared with established methods. J Rheumatol 1984, 11:507-511.
22. Gran JT: An epidemiological survey of the signs and symptoms of ankylosing spondylitis. Clin Rheumatol 1985, 4:161-169.
23. Lee JH, Jun JB, Jung S, Bae SC, Yoo DH, Kim TY, Kim SY, Kim TH: Higher prevalence of peripheral arthritis among ankylosing spondylitis patients. J Korean Med Sci 2002, 17:669-673.
24. Dwosh IL, Resnick D, Becker MA: Hip involvement in ankylosing spondylitis. Arthritis Rheum 1976, 19:683-692.
25. Ward MM: Health-related quality of life in ankylosing spondylitis: a survey of 175 patients. Arthritis Care Res 1999, 12:247-255.
26. Braun J, Sieper J: Therapy of ankylosing spondylitis and other spondyloarthritides: established medical treatment, anti-TNF-α therapy and other novel approaches. Arthritis Res 2002, 4:307-321.
27. Toussirot E, Wendling D: Current guidelines for the drug treatment of ankylosing spondylitis. Drugs 1998, 56:225-240.
28. Uhrin Z, Kuzis S, Ward MM: Exercise and changes in health status in patients with ankylosing spondylitis. Arch Intern Med 2000, 160:2969-2975.
29. Calin A, Elswood J: A prospective nationwide cross-sectional study of NSAID usage in 1331 patients with ankylosing spondylitis. J Rheumatol 1990, 17:801-803.
30. Dougados M, Behier JM, Jolchine I, Calin A, Van Der Heijde D, Olivieri I, Zeidler H, Herman H: Efficacy of celecoxib, a cyclooxygenase 2-specific inhibitor, in the treatment of ankylosing spondylitis: a six-week controlled study with comparison against placebo and against a conventional nonsteroidal antiinflammatory drug. Arthritis Rheum 2001, 44:180-185.
31. Maugars Y, Mathis C, Berthelot JM, Charlier C, Prost A: Assessment of the efficacy of sacroiliac corticosteroid injections in spondylarthropathies: a double-blind study. Br J Rheumatol 1996, 35:767-770.
32. Dougados M, vam der Linden S, Leirisalo-Repo M, Huitfeldt B, Juhlin R, Veys E, Zeidler H, Kvien TK, Olivieri I, Dijkmans B: Sulfasalazine in the treatment of spondylarthropathy: a randomized, multicenter, double-blind, placebo-controlled study. Arthritis Rheum 1995, 38:618-627.
33. Sampaio-Barros PD, Costallat LTL, Bertolo MB, Neto JFM, Samara AM: Methotrexate in the treatment of ankylosing spondylitis. Scand J Rheumatol 2000, 29:160-162.
34. Paulus HE, Bulpitt KJ: DC-ART classification: review of relevant clinical studies. J Rheumatol Suppl 1994, 41:8-20.
35. Braun J, de Keyser F, Brandt J, Mielants H, Sieper J, Veys E: New treatment options in spondyloarthropathies: increasing evidence for significant efficacy of anti-tumor necrosis factor therapy. Curr Opin Rheumatol 2001, 13:245-249.
36. Medical Economics Company, Inc: Prescribing information: Enbrel®. In Physicians' Desk Reference®. Montvale, NJ; 2002: 3504-3507.
37. Centocor, Inc: Remicade: package insert, revised June 2002. Malvern, PA; 2002.
38. Scallon B, Cai A, Solowski N, Rosenberg A, Song XY, Shealy D, Wagner C: Binding and functional comparisons of two types of tumor necrosis factor antagonists. J Pharmacol Exp Ther 2002, 301:418-426.
39. Targan SR, Hanauer SB, van Deventer SJH, Mayer L, Present DH, Braakman T, DeWoody KL, Schaible TF, Rutgeerts PJ, for the Crohn's Disease cA2 Study Group: A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor α for Crohn's disease. N Engl J Med 1997, 337:1029-1035.
40. Hanauer SB, Feagan BG, Lichentenstein GR, Mayer LF, Schreiber S, Colombel JF, Rachmilewitz D, Wolf DC, Olson A, Bao W, Rutgeerts P, and the ACCENT I Study Group: Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002, 359:1541-1549.
41. Sandborn WJ, Hanauer SB, Katz S, Safdi M, Wolf DG, Baerg RD, Tremaine WJ, Johnson T, Diehl NN, Zinsmeister AR: Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology 2001, 121:1088-1094.
42. Gorman JD, Sack KE, Davis JC Jr: Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor α. N Engl J Med 2002, 346:1349-1356.
43. Gorman JD, Sack KE, Davis JC: An open-label trial of etanercept in the treatment of ankylosing spondylitis. Arthritis Rheum 2001, 44(Suppl9):S91.
44. Anderson JJ, Baron G, Van Der Heijde D, Felson DT, Dougados M: Ankylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitis. Arthritis Rheum 2001, 44:1876-1886.
45. Calin A, Garrett S, Whitelock H, Kennedy LG, O'Hea J, Mallorie P, Jenkinson T: A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol 1994, 21:2281-2285.
46. Gorman JD, Sack KE, Davis JC Jr: Inhibition of tumor necrosis factor α and ankylosing spondylitis. N Engl J Med 2003, 348: 360-361.
47. Mander M, Simpson JM, McLellan A, Walker D, Goodacre JA, Dick WC: Studies with an enthesis index as a method of clinical assessment in ankylosing spondylitis. Ann Rheum Dis 1987, 46:197-202.
48. Clegg DO, Reda DJ, Weisman MH, Blackburn WD, Cush JJ, Cannon GW, Mahowald ML, Schumacher HR Jr, Taylor T, Budiman-Mak E, Cohen MR, Vasey FB, Luggen ME, Mejias E, Silverman SL, Makkena R, Alepa FP, Buxbaum J, Haakenson CM, Ward RH, Manaster BJ, Anderson RJ, Ward JR, Henderson WG: Comparison of sulfasalazine and placebo in the treatment of ankylosing spondylitis. A Department of Veterans Affairs Cooperative Study. Arthritis Rheum 1996, 39:2004-2012.
49. Brandt J, Kariouzov A, Listing J, Haibel H, Sörensen H, Grassnickel L, Sieper J, Braun J: Six month results of a German double-blind placebo controlled, phase-III clinical trial of etanercept in active ankylosing spondylitis. Arthritis Rheum 2002, 46(9 Suppl):S429.
50. Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A: A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 1994, 21:2286-2291.
51. Ware JE Jr, Sherbourne CD: The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992, 30:473-483.
52. Brandt J, Haibel H, Cornely D, Golder W, Gonzalez J, Reddig J, Thriene W, Sieper J, Braun J: Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor α monoclonal antibody infliximab. Arthritis Rheum 2000, 43: 1346-1352.
53. Jenkinson TR, Mallorie PA, Whitelock HC, Kennedy LG, Garrett SL, Calin A: Defining spinal mobility in ankylosing spondylitis (AS). The Bath AS Metrology Index. J Rheumatol 1994, 21: 1694-1698.
54. Brandt J, Haibel H, Sieper J, Reddig J, Braun J: Infliximab treatment of severe ankylosing spondylitis: one-year followup. Arthritis Rheum 2001, 44:2936-2937.
55. Braun J, Brandt J, Listing J, Zink A, Alten R, Golder W, Gromnicalhle E, Kellner H, Krause A, Schneider M, Sörensen H, Zeidler H, Thriene W, Sieper J: Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet 2002, 359:1187-1193.
56. Brandt J, Listing J, Alten R, Burmester GR, Gromnica-Ihle E, Schneider M, Sörensen H, Zeidler H, Reddig J, Sieper J, Braun J: One year results of a double-blind placebo controlled, phase-III clinical trial of infliximab in active ankylosing spondylitis. Arthritis Rheum 2002, 46(9 Suppl):S429.
57. Stone M, Salonen D, Lax M, Payne U, Lapp V, Inman R: Clinical and imaging correlates of response to treatment with infliximab in patients with ankylosing spondylitis. J Rheumatol 2001, 28:1605-1614.
58. Maksymowych WP, Jhangri GS, Lambert RG, Mallon C, Buenviaje H, Pedrycz E, Luongo R, Russell AS: Infliximab in ankylosing spondylitis: a prospective observational inception cohort analysis of efficacy and safety. J Rheumatol 2002, 29:959-965.
59. Van den Bosch F, Kruithof E, Baeten D, Herssens A, de Keyser F, Mielants H, Veys EM: Randomized double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor α (infliximab) versus placebo in active spondyloarthropathy. Arthritis Rheum 2002, 46:755-765.
60. Braun J, Bollow M, Sieper J: Radiologic diagnosis and pathology of the spondyloarthropathies. Rheum Dis Clin North Am 1998, 24:697-735.
61. Braun J, Van Der Heijde D: Imaging and scoring in ankylosing spondylitis. Besf Pract Res Clin Rheumatol 2002, 16:573-604.
62. Braun J, Baraliakos X, Golder W, Listing J, Brandt J, Bollow M, Sieper J, Van Der Heijde D: Improvement of spinal inflammation in ankylosing spondylitis (AS) by infliximab therapy as assessed by a magnetic resonance imaging (MRI) using a novel evaluated spinal scoring system-results of a double-blind placebo-controlled trial. Arthritis Rheum 2002, 46(9 Suppl):S426.
63. Braun J, Baraliakos X, Golder W, Listing J, Brandt J, Bollow M, Sieper J, Van Der Heijde D: Ankylosing spondylitis (AS) - development and evaluation of a spinal scoring system (ASspiMIR) using magnetic resonance imaging (MRI) in patients with active disease. Arthritis Rheum 2002, 46 (9 Suppl):S426.